Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMN AMN Healthcare Services	$21.09	$20.83	$17.45 ▼ $70.07	$807.43M	0.16	912,341 shs	868,983 shs
DNLI Denali Therapeutics	$13.18 -2.7%	$13.86	$10.57 ▼ $33.33	$1.91B	1.49	1.11 million shs	1.21 million shs
INMD InMode	$14.69 +0.7%	$15.27	$13.68 ▼ $19.85	$928.54M	2.02	1.18 million shs	1.17 million shs
NARI Inari Medical	$79.97	$79.97	$39.76 ▼ $79.99	$4.68B	1.02	1.33 million shs	N/A

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMN AMN Healthcare Services	-0.09%	-2.81%	+4.62%	-16.82%	-61.02%
DNLI Denali Therapeutics	+3.83%	-0.88%	-17.94%	-18.24%	-24.94%
INMD InMode	+1.39%	+1.81%	+1.18%	-22.06%	-22.23%
NARI Inari Medical	0.00%	0.00%	0.00%	0.00%	+60.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMN AMN Healthcare Services	4.4324 of 5 stars	3.1	2.0	0.8	4.3	3.4	1.7	1.9
DNLI Denali Therapeutics	4.4624 of 5 stars	4.5	1.0	0.0	4.7	3.7	2.5	0.0
INMD InMode	3.8279 of 5 stars	4.1	3.0	0.0	0.0	3.4	1.7	1.9
NARI Inari Medical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMN AMN Healthcare Services	2.25	Hold	$32.08	52.13% Upside
DNLI Denali Therapeutics	3.06	Buy	$33.71	155.80% Upside
INMD InMode	2.13	Hold	$18.54	26.22% Upside
NARI Inari Medical	2.14	Hold	$69.22	-13.44% Downside

Current Analyst Ratings Breakdown

Latest AMN, NARI, DNLI, and INMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
5/13/2025	AMN AMN Healthcare Services	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $25.50
5/8/2025	DNLI Denali Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $29.00
5/7/2025	DNLI Denali Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
5/7/2025	DNLI Denali Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $32.00
4/30/2025	INMD InMode	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $24.00
4/29/2025	INMD InMode	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$19.00 ➝ $16.25
4/29/2025	INMD InMode	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$17.00 ➝ $15.00
4/29/2025	INMD InMode	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
4/28/2025	INMD InMode	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/28/2025	INMD InMode	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$22.00 ➝ $16.00

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMN AMN Healthcare Services	$2.85B	0.28	$5.91 per share	3.57	$18.56 per share	1.14
DNLI Denali Therapeutics	$330.53M	5.79	N/A	N/A	$7.42 per share	1.78
INMD InMode	$392.41M	2.37	$1.41 per share	10.40	$10.12 per share	1.45
NARI Inari Medical	$493.63M	9.48	$0.09 per share	906.95	$8.07 per share	9.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMN AMN Healthcare Services	-$146.98M	-$4.33	N/A	8.71	N/A	-4.93%	15.22%	4.72%	8/14/2025 (Estimated)
DNLI Denali Therapeutics	-$145.22M	-$2.67	N/A	N/A	N/A	N/A	-32.94%	-30.04%	8/7/2025 (Estimated)
INMD InMode	$181.27M	$2.33	6.25	8.07	N/A	45.91%	18.25%	16.33%	8/7/2025 (Estimated)
NARI Inari Medical	-$1.64M	-$1.35	N/A	727.00	N/A	-13.68%	-10.09%	-6.60%	N/A

Latest AMN, NARI, DNLI, and INMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	AMN AMN Healthcare Services	$0.19	$0.45	+$0.26	-$0.03	$670.08 million	$689.53 million
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.71	-$0.78	-$0.07	-$0.78	$3.24 million	N/A
4/28/2025	Q1 2025	INMD InMode	$0.45	$0.31	-$0.14	$0.26	$82.21 million	$77.87 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMN AMN Healthcare Services	$1.20	5.69%	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
INMD InMode	N/A	N/A	N/A	N/A	N/A
NARI Inari Medical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMN AMN Healthcare Services	1.49	1.09	1.18
DNLI Denali Therapeutics	N/A	9.98	9.98
INMD InMode	N/A	10.23	9.38
NARI Inari Medical	N/A	1.77	1.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMN AMN Healthcare Services	99.23%
DNLI Denali Therapeutics	92.92%
INMD InMode	68.04%
NARI Inari Medical	90.98%

Insider Ownership

Company	Insider Ownership
AMN AMN Healthcare Services	0.93%
DNLI Denali Therapeutics	12.50%
INMD InMode	6.92%
NARI Inari Medical	10.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMN AMN Healthcare Services	4,230	38.29 million	37.72 million	Optionable
DNLI Denali Therapeutics	430	145.28 million	132.55 million	Optionable
INMD InMode	480	63.21 million	64.75 million	Optionable
NARI Inari Medical	800	58.54 million	52.34 million	Optionable

AMN, NARI, DNLI, and INMD Headlines

Recent News About These Companies

Thrombectomy system removes clots, improves quality of life for patients with PE

May 20, 2025 | healio.com

The top nitinol cardiac medtech news of 2025 (so far)

May 13, 2025 | medicaldesignandoutsourcing.com

Stryker outlines 2025 growth targets with 8.5%-9.5% organic sales growth and $13.20-$13.45 EPS

May 2, 2025 | msn.com

Expert Testimony Supporting POPR Can Be An Effective Strategy

April 21, 2025 | jdsupra.com

Volta Medical Appoints Bill Hoffman as Executive Chairman of the Board of Directors

April 8, 2025 | finance.yahoo.com

8 spine, orthopedic acquisitions in Q1

March 27, 2025 | beckersspine.com

Okami Medical Announces Portfolio Expansion with the Addition of the SENDERO® MAX Delivery Catheter

March 26, 2025 | finance.yahoo.com

How Is Inari Medical Inc. (NASDAQ:NARI) Positioned in the Medical Devices Sector?

March 25, 2025 | kalkinemedia.com

If You Could Only Hold 3 Investments for Life, Consider These (NARI)

March 10, 2025 | marketbeat.com

Stryker’s Inari Medical Launches Artix Thrombectomy System

March 7, 2025 | evtoday.com

Stryker’s Inari Medical launches Artex thrombectomy system

March 7, 2025 | massdevice.com

Inari Medical introduces thrombectomy system for arterial thrombus cases

March 7, 2025 | msn.com

Inari Medical acquisition could provide Stryker with foothold in peripheral vascular market

February 28, 2025 | expresshealthcare.in

Wearable defibrillator maker Kestra Medical plots $150M IPO

February 26, 2025 | fiercebiotech.com

Stryker grows cardiovascular division with Inari Medical acquisition

February 24, 2025 | medicaldevice-network.com

Stryker Completes Acquisition of Inari

February 20, 2025 | evtoday.com

Stryker concludes Inari Medical acquisition for $4.9bn

February 20, 2025 | finance.yahoo.com

Stryker completes Inari Medical acquisition

February 20, 2025 | beckersspine.com

Inari Medical, Inc. (NARI): the Best Performing Healthcare Stock So Far in 2025

February 20, 2025 | msn.com

Stryker completes acquisition of Inari Medical

February 19, 2025 | massdevice.com

Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment

February 19, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
By Leo Miller | May 27, 2025
View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
By Sam Quirke | May 13, 2025
View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
Super Micro Computer Stock Clears New Path Higher on Saudi Orders
By Gabriel Osorio-Mazilli | May 22, 2025
View Super Micro Computer Stock Clears New Path Higher on Saudi Orders
Survey: America’s Most Inspirational Women Business Leaders [2025]
By MarketBeat Staff | May 7, 2025
View Survey: America’s Most Inspirational Women Business Leaders [2025]

AMN, NARI, DNLI, and INMD Company Descriptions

AMN Healthcare Services NYSE:AMN

$21.09 0.00 (0.00%)

Closing price 03:59 PM Eastern

Extended Trading

$21.12 +0.02 (+0.12%)

As of 04:21 PM Eastern

AMN Healthcare Services, Inc. provides healthcare workforce solutions and staffing services to healthcare facilities in the United States. It operates through three segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. The Nurse and Allied Solutions segment offers travel nurse staffing, labor disruption staffing, local staffing, international nurse and allied permanent placement, and allied staffing solutions. The Physician and Leadership Solutions segment provides locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement solutions. The Technology and Workforce Solutions segment offers language services, vendor management systems, workforce optimization, and outsourced solutions. The company also provides allied health professionals, such as physical therapists, respiratory therapists, occupational therapists, medical and radiology technologists, lab technicians, speech pathologists, rehabilitation assistants, and pharmacists. It offers its services under the brands, including AMN Healthcare, Nursefinders, HealthSource Global Staffing, O'Grady Peyton International, Connetics, Medical Search International, DRW Healthcare Staffing, and B.E. Smith. AMN Healthcare Services, Inc. was founded in 1985 and is headquartered in Dallas, Texas.

Denali Therapeutics NASDAQ:DNLI

$13.18 -0.36 (-2.66%)

Closing price 04:00 PM Eastern

Extended Trading

$13.45 +0.27 (+2.05%)

As of 05:30 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

InMode NASDAQ:INMD

$14.69 +0.10 (+0.69%)

Closing price 04:00 PM Eastern

Extended Trading

$14.64 -0.05 (-0.37%)

As of 05:46 PM Eastern

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

Inari Medical NASDAQ:NARI

$79.97 0.00 (0.00%)

As of 02/19/2025

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time